[阿霉素对急性呼吸道病毒感染的预防作用评估]
[Evaluation of amyxin effect in prophylaxis of acute respiratory viral infections].
作者信息
Sel'kova E P, Iakovlev V N, Semenenko T A, Filatov N N, Gotvianskaia T P, Danilina G A, Pantiukhova T N, Nikitina G Iu, Tur'ianov M Kh
机构信息
Botkin City Clinical Hospital, Gamaleya Research Institute of Epidemiology and Mikrobiology, Medical Academy of Post-Diploma Education, Central State Sanitary and Epidemiological Inspection, Moscow, Russia.
出版信息
Zh Mikrobiol Epidemiol Immunobiol. 2001 May-Jun(3):42-6.
The results of the evaluation of the oral inductor of endogenic interferon (amyxin), manufactured in Russia are presented. The use of amyxin was found to produce a drop in morbidity in acute respiratory virus infections (ARVI) among medical workers 3.4 times, i.e. the preparation exhibited a pronounced prophylactic effect with respect to ARVI. The use of the preparation was accompanied by a decrease in the number of manifest forms of ARVI. Persons given the preparation often had ARVI in a mild or asymptomatic form.
本文展示了对俄罗斯生产的内源性干扰素口服诱导剂（氨米xin）的评估结果。研究发现，使用氨米xin可使医务人员急性呼吸道病毒感染（ARVI）的发病率降低3.4倍，即该制剂对ARVI具有显著的预防作用。使用该制剂还伴随着ARVI明显症状形式数量的减少。服用该制剂的人通常患的是轻度或无症状形式的ARVI。
Zotero 插件